Related factors between romosozumab, a sclerostin monoclonal antibody, and bone mineral density as well as bone turnover markers: A prospective observational study

Related factors between romosozumab, a sclerostin monoclonal antibody, and bone mineral density as well as bone turnover markers: A prospective observational study - Related factors between romosozumab, a sclerostin monoclonal antibody, and bone mineral density as well as bone turnover markers: A prospective observational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038154

Enrollment

100

Registered

2019-10-01

Start date

2019-10-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with osteoporosis who come to Internal Medicine 1 in Shimane University and agree with participation in this stusy

Exclusion criteria

Exclusion criteria: nothing

Design outcomes

Primary

Measure	Time frame
Background (interview) general blood, urine markers bone-metabolism related markers BMD X ray	—

Secondary

Measure	Time frame
screlostin (pg/mL) abodominal CT	—

Countries

Japan

Contacts

Public ContactKen-chiro Tanaka

Shimane University Internal medicine 1

ken1nai@med.shimane-u.ac.jp0853-20-2183

Outcome results